Cardiovascular Pharmacogenetics: 160 (Handbook of Experimental Pharmacology, 160) - Tapa dura

Libro 69 de 124: Handbook of Experimental Pharmacology

Wilkins, M. R.; Wilkins, Martin R.

 
9783540402046: Cardiovascular Pharmacogenetics: 160 (Handbook of Experimental Pharmacology, 160)
Tapa dura
ISBN 10: 3540402047 ISBN 13: 9783540402046
Editorial: Springer, 2003

Sinopsis

The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi­ nimising the risks of an adverse event. Taking the idea further, pundits have pre­ dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as­ ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware­ ness of variation in drug metabolism and was correctly assigned to genetic poly­ morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera­ se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

"Sinopsis" puede pertenecer a otra edición de este libro.

Reseña del editor

The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi­ nimising the risks of an adverse event. Taking the idea further, pundits have pre­ dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as­ ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware­ ness of variation in drug metabolism and was correctly assigned to genetic poly­ morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera­ se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

Reseña del editor

This volume intends to provide a panorama of our current understanding of the role of genetic information in the management of cardiovascular disease. A recurring plea from the contributors is the need for more hypothesis-driven, rigorously conducted and analysed clinical research. Perhaps this compilation of knowledge will provide a springboard for the design of informative clinical studies.

"Sobre este título" puede pertenecer a otra edición de este libro.

Editorial
Springer
Año de publicación
2003
Idioma
Inglés
ISBN 10 
3540402047
ISBN 13 
9783540402046
Encuadernación
Tapa dura
Número de páginas
422
Editor
Wilkins Martin R.
Contacto del fabricante
ProductSafety@springernature.com
ProductSafety@springernature.com

Poststr. 9
Darmstadt
64293
Alemania

Otras ediciones populares con el mismo título

9783642072918: Cardiovascular Pharmacogenetics: 160 (Handbook of Experimental Pharmacology)

Edición Destacada

ISBN 10:  3642072917 ISBN 13:  9783642072918
Editorial: Springer, 2011
Tapa blanda